6th Annual KAPAL Conference Brings Maryland, South Korea Together

KAPAL Conference
Published on : Published by : Alex Keown

6th Annual KAPAL Conference Brings Maryland, South Korea Together The distance between Maryland and South Korea will shorten next week when the Korean American Professional Association in Life Sciences (KAPAL) [….]

FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the Treatment of Glioblastoma Multiforme

Published on : Published by : BioBuzz Media

NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted NT-I7 (efineptakin alfa) (rhIL-7-hyFc) Orphan Drug Designation for the treatment of Glioblastoma Multiforme.

A Study in Nature Communications Reports that NeoImmuneTech’s NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

Published on : Published by : BioBuzz Media

NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused therapeutics company, reported that Nature Communications (Impact Factor: 14.92) published the results of an in vivo study combining the long-acting human IL-7, NT-I7, with chimeric antigen receptor (CAR) T cells directed against CD19+ B cell lymphoma and acute myeloid leukemia.

NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

Published on : Published by : BioBuzz Media

NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022. These include one poster discussion and two poster displays.

NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022

Published on : Published by : BioBuzz Media

NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, presented the broad combination potential of its long-acting IL-7 candidate – NT-I7 (efineptakin alfa) (rhIL-7-hyFc) – at the American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana, United States, April 8-13 2022.

Rockville’s NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 and Opdivo®

Published on : Published by : BioBuzz Media

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced the first Clinical Trial Application (CTA) authorization in the European Union (EU). This authorization comes from Italy’s Agenzia Italiana Del Farmaco (AIFA) for the company’s ongoing Phase 2 study of NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), in combination with Bristol-Myers Squibb Company’s (NYSE: BMY) Opdivo® (nivolumab), a PD-1 blocking antibody, versus nivolumab monotherapy.

Rockville’s NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

Published on : Published by : BioBuzz Media

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the pilot study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in progressive multifocal leukoencephalopathy (PML), a rare but very aggressive, opportunistic brain infection. PML is caused by the reactivation of John Cunningham virus (JCV) in immunocompromised individuals, and there are currently no approved therapies for this illness. This investigator-initiated study is being led by Irene Cortese, M.D., of the National Institute of Neurological Disorders and Stroke (NINDS)/National Institute of Health (NIH).

Rockville’s NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors

Published on : Published by : BioBuzz Media

Rockville’s NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), [….]

NeoImmuneTech Announces Closing of Initial Public Offering

Published on : Published by : BioBuzz Media

NeoImmuneTech Announces Closing of Initial Public Offering ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the closing of its initial public offering of 3,133,334 [….]